ACRO Biomedical Reports No Revenue and Increased Losses in Q2 2026

ACRO Biomedical Co., Ltd. reported its financial results for the second quarter of 2026, revealing a continued lack of revenue and a significant increase in operating losses compared to the previous year. For the three months ending June 30, 2026, the company recorded no revenue, consistent with the same period in 2025. Operating expenses rose to $17,554, up from $13,614 in the prior year, leading to a net loss of $21,356, compared to a loss of $15,562 in the same quarter of 2025. For the first half of 2026, the company also reported no revenue, with operating expenses increasing to $77,825 from $22,548 in the first half of 2025, resulting in a net loss of $65,130, compared to a loss of $25,863 in the previous year.

The company's balance sheet as of June 30, 2026, showed total current assets of $3,648, a decrease from $14,098 at the end of 2025. Current liabilities increased to $448,437 from $401,062, resulting in a working capital deficiency of $444,789, up from $386,964 at the end of the previous fiscal year. The increase in liabilities was primarily due to higher accounts payable and amounts due to related parties. The company continues to rely heavily on advances from a minority stockholder to fund its operations, which raises concerns about its ability to sustain operations without generating revenue.

Strategically, ACRO Biomedical has not made significant progress in product development or market expansion. The company has not generated any revenue since December 2022 and has not launched any new products despite previous efforts in research and development. The company’s focus has been on cordyceps-related products, which have not yielded any sales since 2018. The lack of a trading market for its common stock further complicates its ability to raise funds, as the stock is currently traded on the OTC Market Group’s Pink Limited Market, limiting investor interest and liquidity.

Management has expressed substantial doubt about the company's ability to continue as a going concern, citing minimal cash reserves and ongoing operating losses. The company has no full-time employees, with its CEO working part-time without compensation. The financial statements indicate that the company must secure additional funding to implement its business plans, but there are no agreements in place for future financing. The outlook remains uncertain, as the company has not established a clear path to revenue generation or product development, and it faces significant operational and financial challenges moving forward.